Here we report a metastatic TFEB-translocated, but not amplified, renal cell carcinoma in a kidney transplant patient who was consequently treated with immune therapy and tyrosine kinase inhibitors and provide a review of the current literature. Here, TFEB is linked to renal cell carcinoma.